These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3802380)

  • 21. Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice.
    Cummings J; Double JA; Bibby MC; Farmer P; Evans S; Kerr DJ; Kaye SB; Smyth JF
    Cancer Res; 1989 Jul; 49(13):3587-93. PubMed ID: 2731178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
    Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD
    Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer.
    Marchbanks K; Dudley MN; Posner MR; Darnowski J
    Pharmacotherapy; 1995; 15(4):451-7. PubMed ID: 7479197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I clinical investigation of amonafide.
    Saez R; Craig JB; Kuhn JG; Weiss GR; Koeller J; Phillips J; Havlin K; Harman G; Hardy J; Melink TJ
    J Clin Oncol; 1989 Sep; 7(9):1351-8. PubMed ID: 2549205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of gallium nitrate in man.
    Kelsen DP; Alcock N; Yeh S; Brown J; Young C
    Cancer; 1980 Nov; 46(9):2009-13. PubMed ID: 7427907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
    de Jong J; Geijssen GJ; Munniksma CN; Vermorken JB; van der Vijgh WJ
    J Clin Oncol; 1992 Dec; 10(12):1897-906. PubMed ID: 1453205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.
    Yoon EJ; Lee WI; Shim HJ; Lee SD; Kim WB; Yang J; Lee MG
    Biopharm Drug Dispos; 1996 Jul; 17(5):373-420. PubMed ID: 8830976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
    Ryan DP; Supko JG; Eder JP; Seiden MV; Demetri G; Lynch TJ; Fischman AJ; Davis J; Jimeno J; Clark JW
    Clin Cancer Res; 2001 Feb; 7(2):231-42. PubMed ID: 11234874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors.
    Rafi I; Boddy AV; Calvete JA; Taylor GA; Newell DR; Bailey NP; Lind MJ; Green M; Hines J; Johnstone A; Clendeninn N; Calvert AH
    J Clin Oncol; 1998 Mar; 16(3):1131-41. PubMed ID: 9508200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I trial and clinical pharmacology of elsamitrucin.
    Raber MN; Newman RA; Newman BM; Gaver RC; Schacter LP
    Cancer Res; 1992 Mar; 52(6):1406-10. PubMed ID: 1540949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
    Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
    Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disposition of mitoxantrone in cancer patients.
    Alberts DS; Peng YM; Leigh S; Davis TP; Woodward DL
    Cancer Res; 1985 Apr; 45(4):1879-84. PubMed ID: 3978648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacologic fate of the antitumor agent 2-amino-1,3,4-thiadiazole in the dog.
    Lu K; Loo TL
    Cancer Chemother Pharmacol; 1980; 4(4):275-9. PubMed ID: 7438330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing.
    Mross K; Holländer N; Frost A; Unger C; Ziroli V; Massing U
    Onkologie; 2006 Oct; 29(10):444-50. PubMed ID: 17028453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer.
    Reece PA; Morris RG; Bishop JF; Olver IN; Raghavan D
    Cancer Res; 1987 Jun; 47(11):2996-9. PubMed ID: 2952262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacokinetics of irinotecan.
    Chabot GG
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
    Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
    Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent.
    Egorin MJ; Zuhowski EG; Sentz DL; Dobson JM; Callery PS; Eiseman JL
    Cancer Chemother Pharmacol; 1999; 44(4):283-94. PubMed ID: 10447575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.